GAINESVILLE and BOCA RATON, Fla., Dec. 5, 2016 /PRNewswire-USNewswire/ — The Florida Institute for the Commercialization of Public Research (the Florida Institute) announced today that it has finalized a funding agreement SegAna, LLC, an Orlando-based company with technology developed at University of Central Florida. The Florida Institute supports new company creation based on publicly-funded research, and bridges early funding gaps for companies spinning out of Florida-based universities and research institutions.
SegAna is a medical technology company that will produce deformable four-dimensional lung phantom simulators for enhancing lung cancer radiation treatment. SegAna’s lung phantoms are 3-D printed with patient specific details, including elastic and radiographic properties. The lung phantom, when coupled with SegAna’s simulator, trains the physician to develop precise treatment parameters which are translated directly to the patient’s radiation treatment.
“Lung cancer is the most common cancer worldwide and accounts for more deaths than any other cancer in the U.S.,” said Rodney Bosley, SegAna, LLC, Chief Executive Officer. “Our patent pending state of art technology will enhance the treatment of lung cancer by training the physician to accurately treat the tumor during normal breathing of the lung, which reduces radiation damage to lung tissue surrounding the cancer and ultimately improving patient outcomes.”
“There are over 220,000 new lung cancer cases reported annually in the United States, and an estimated 80% of the cases are treated with radiation therapy,” said Jackson Streeter, MD, Florida Institute Chief Executive Officer. “The Institute looks forward to supporting SegAna as the company works to improve lung cancer treatment and associated outcomes for patients fighting this disease.”
About the Florida Institute
Formed by the Florida Legislature in 2007, the Florida Institute for the Commercialization of Public Research is a non-profit organization that works collaboratively with the technology licensing and commercialization offices of Florida’s state universities and private research institutions to leverage a $2B+ research base and form investable companies that create clean jobs in new industries that are driving the global economy. With funding from the State of Florida through the Department of Economic Opportunity, and through the generosity of mentors, advisors and donors, the Institute provides company building services, and seed funding through the Florida Technology Seed Capital Fund, to promising Florida startups. Sixty-one companies have been funded to date, and the Institute’s economic impact through June 30, 2016 in the State of Florida was $630 million.
About SegAna, LLC.
SegAna, LLC, is a medical technology startup company that will manufacture and sell deformable four-dimensional lung phantom simulators for enhancing lung cancer radiation treatment. Each phantom is manufactured with the patient’s specific lung details which trains the physician to develop precise treatment parameters.
Chief Operating Officer
Institute for the Commercialization of Public Research
SOURCE Florida Institute for the Commercialization of Public Research